Median: positive results to come from San Diego

(CercleFinance.com) - Median Technologies announced on Thursday that it plans to share the latest advances in its medical software dedicated to the diagnosis of lung cancer at a medical congress opening this weekend in San Diego (California).


The French 'medtech' explains that it intends in particular to revisit the positive results of its first pivotal study, which showed last week that the eyonis LCS device had achieved unprecedented detection accuracy in the analysis of scanner images.

For the record, its eyonis LCS system uses artificial intelligence and machine learning to diagnose lung cancers at an early stage.

The trial even included low-dose CT images in its cohort, which were considered difficult to analyze.

Despite this good news, Median's share price fell by 28% over the last six trading sessions, despite the fact that the success of the study is the first of two steps needed to access the European and American markets.

The first results of the second pivotal study will be released in the first quarter of 2025.

Median then expects to file regulatory applications for marketing approval of eyonis LCS in the US and Europe in the first half of 2025.

Following the announcement of its participation in the IASLC's World Conference on Lung Cancer 2024 from September 7 to 10, Median rebounded by almost 6% on the stock market on Thursday morning.

The share is still up 23% since the start of the year.

Copyright (c) 2024 CercleFinance.com. All rights reserved.